2 results
Approved WMOCompleted
The primary objectives of this study are: - To evaluate the efficacy of GFT505 80mg and GFT505 120mg once daily (according to adaptive design, after 6-month interim safety analysis of the 80mg data on at least 50% of patients) for 52 weeks versus…
Approved WMOCompleted
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of MTAU9937A in patients with prodromal or mild Alzheimer*s disease (AD), ages 50*80, who are amyloid positive by cerebrospinal fluid (CSF) or amyloid positron…